Posaconazole
- Generic Name
- Posaconazole
- Brand Names
- Noxafil, Posanol, Posaconazole Accord, Posaconazole AHCL
- Drug Type
- Small Molecule
- Chemical Formula
- C37H42F2N8O4
- CAS Number
- 171228-49-2
- Unique Ingredient Identifier
- 6TK1G07BHZ
- Background
Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
- Indication
For prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), or due to hematologic malignancies with prolonged neutropenia from chemotherapy. Also for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole. Posaconazole is used as an alternative treatment for invasive aspergillosis, Fusarium infections, and zygomycosis in patients who are intolerant of, or whose disease is refractory to, other antifungals.
- Associated Conditions
- Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Invasive Aspergillosis, Invasive bronchopulmonary aspergillosis, Mucormycosis, Oropharyngeal Candidiasis, Prophylaxis of Aspergillus infection, Pulmonary cryptococcosis infection
- Associated Therapies
- -
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2018-05-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 113
- Registration Number
- NCT01200355
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole
- First Posted Date
- 2010-07-15
- Last Posted Date
- 2013-09-10
- Lead Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
- Target Recruit Count
- 78
- Registration Number
- NCT01162967
- Locations
- 🇪🇸
International Health Unit Drassanes, Barcelona, Spain
🇪🇸Infectious Disease Department Vall d'Hebron Hospital, Barcelona, Spain
🇪🇸International Health Unit Metropolitana Nord, Santa Coloma, Barcelona, Spain
Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520)
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 279
- Registration Number
- NCT01075984
Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00936117
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir
- Conditions
- Fungal InfectionHIV Infection
- Interventions
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT00817765
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands
Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 63
- Registration Number
- NCT00811642
Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 252
- Registration Number
- NCT00811928
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
- Conditions
- Hematologic MalignanciesInvasive Fungal Infections
- Interventions
- Drug: PosaconazoleDrug: ABLC
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT00750737
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Post-marketing Surveillance Study of Invasive Mycosis With Posaconazole (Study P04641)
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 214
- Registration Number
- NCT00726609
Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
- Conditions
- Fungal InfectionAcute Myelogenous LeukemiaNeutropenia
- Interventions
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 75
- Registration Number
- NCT00686543
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.